Fate of HDL drug research awaits cardiology meeting

03/18/2007 | MSNBC

The fate of torcetrapib as a safe and effective treatment to raise levels of "good" cholesterol could be determined at an annual cardiology meeting. Drugmakers are studying drugs in the same class as torcetrapib, which Pfizer pulled from clinical trials after associated deaths, and researchers are expected to report on their status at the American College of Cardiology meeting.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC